2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/19/16NantHealth to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 9
CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 19, 2016-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that the company will present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017, at 5 p.m. Pacific Standard Time at the Westin St. Francis Hotel in San Francisco. An audio-only webcast of the presentation will be available at www.NantHealth.com. ... 
Printer Friendly Version
12/16/16NantHealth, Inc. Announces Pricing of $100 Million of 5.50% Convertible Notes
CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 16, 2016-- NantHealth, Inc. (Nasdaq: NH) today announced the pricing of an aggregate of $100 million principal amount of 5.50% Convertible Senior Notes due 2021 (the "Notes"), in a private offering to qualified institutional buyers pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the "Act"), and a separate concurrent private placement under Section 4(a)(2) of the Act to... 
Printer Friendly Version
12/15/16NantHealth, Inc. Announces Proposed $100 Million Convertible Notes Offering
CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 15, 2016-- NantHealth, Inc. (Nasdaq: NH) today announced its intention to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Act”). NantHealth also intends to grant t... 
Printer Friendly Version
12/13/16NantHealth Expands Adoption of GPS CancerTM with New Florida Genomics Lab License and Successful Adoption by Florida Community Oncologists
Florida-based community oncologists leverage advanced molecular profile for decision support Doctors report that patients find hope in additional care options with good outcomes CULVER CITY, Calif. & SARASOTA, Fla.--(BUSINESS WIRE)--Dec. 13, 2016-- NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has expanded adoption of GPS Cancer, a c... 
Printer Friendly Version
12/13/16NantHealth Added to Nasdaq Biotech Index
CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 13, 2016-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it has been selected by NASDAQ for inclusion in the NASDAQ Biotechnology Index® (NASDAQ: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective at market open on Monday, December 19, 2016. The Index is designed to track the performance o... 
Printer Friendly Version
12/08/16NantHealth, NantKwest and NantOmics Announce Availability of GPS Cancer™ and Phase I – III QUILT Trials Through the U.S. National Institutes of Health’s ClinicalTrials.gov
Patients and physicians can now access active clinical trials for various cancer types including lung, breast, leukemia and more through the largest clinical trials database CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 8, 2016-- NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, together with NantKwest and NantOmics, today announced the public availability of QUILT Programs (Quantum ... 
Printer Friendly Version
12/07/16NantHealth And TransMed Systems Partner to Enable and Inform Community Oncologists of the Most Effective Tools and Technologies for Personalized Cancer Treatments Using GPS Cancer™
Collaboration will provide access to data around real-time outcomes including clinical trial matches and cost analysis to the network of community cancer centers treating patients with rare and common cancers CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 7, 2016-- NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company and TransMed Systems, a company that develops and deploys software solu... 
Printer Friendly Version
12/06/16NantHealth Announces Exclusive Reseller Agreement for GPS Cancer™ with Oncotest-Teva in Israel
Company continues strong momentum for its comprehensive molecular test for cancer care and driving the era of clinical proteomics by landing first international distributor relationship CULVER CITY, Calif. & SHOHAM, Israel--(BUSINESS WIRE)--Dec. 6, 2016-- NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has entered into an exclusive reseller agreement for GPS Cancer, the leading molecular test... 
Printer Friendly Version
12/05/16NantHealth Continues Global Expansion Of GPS Cancer™ By Bringing Advanced Molecular Profiling to Patients in the Middle East Through Partnership with Lunatus
Oncologists in United Arab Emirates, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon will be empowered to make more informed clinical decisions to personalize treatment and care for their patients Partnership builds on international expansion of GPS Cancer which was recently made available in Italy and Israel CULVER CITY, Calif. & DUBAI, United Arab Emirates--(BUSINESS WIRE)--Dec. 5, 2016-- NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, perso... 
Printer Friendly Version
11/07/16NantHealth Reports 76% Increase in Total Q3 Net Revenue 2016 vs 2015, Gross Profit Triples
Rapid Adoption of GPS Cancer with More Than 100% Increase in the Number of Oncologists Ordering the Test from Second to Third Quarter Number of Oncologists Ordering GPS Cancer Increased from 85 in Q2 to 181 in Q3, Representing Patients from over 25 Different Health Plans, with 524 GPS Cancer Tests Ordered in Q3 With Seven Payer Contracts Executed and Upon Completion of the GPS Pilot Trial with Horizon Blue Cross Blue Shield New Jersey, the Number of Covered Cancer Lives Will Increase from 2... 
Printer Friendly Version
11/04/16NantHealth to Report 2016 Third-Quarter Financial Results and Host Conference Call on Monday, November 7
CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 4, 2016-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2016 third quarter on Monday, November 7, 2016 after market close. NantHealth management will host a conference call that same day at 3 p.m. PT (6 p.m. ET) to review the company’s performance and answer questions. The conferen... 
Printer Friendly Version
11/03/16NantHealth Announces Global Expansion of GPS Cancer; Partners with Sorgente to Expand Availability of GPS Cancer™ to Italy
Community oncologists will now have access to comprehensive tests to help them make better informed clinical decisions aimed at personalizing care for their patients Partnership further expands availability of molecular profiling test internationally CULVER CITY, Calif. & MILAN--(BUSINESS WIRE)--Nov. 3, 2016-- NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has entered into an exclusive reseller agre... 
Printer Friendly Version
10/27/16NantHealth Expands GPS Cancer™ Coverage Through Partnership with Horizon Blue Cross Blue Shield of New Jersey and COTA
New Jersey's largest health insurance plan to reimburse for comprehensive molecular test in investigational cancer studies across four mid-Atlantic health systems Health systems who order GPS Cancer will also track cost and outcomes through COTA, a leading oncology analytics software platform HACKENSACK, N.J. & CULVER CITY, Calif.--(BUSINESS WIRE)--Oct. 27, 2016-- NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announc... 
Printer Friendly Version
10/26/16NantHealth Announces Immunotherapy Clinical Trials in the Mid-Atlantic, First Whole Genomics Supercomputing Medical Reasoning Engine Helps Oncologists Make Informed Treatment Decisions for Cancer Patients
Horizon Blue Cross Blue Shield, New Jersey’s largest health insurance plan, to reimburse for GPS CancerTM comprehensive molecular test in investigational cancer studies for certain lung, breast and colon cancers The supercomputing genomics engine, a decade in the making, has successfully completed analyses of more than 21,000 cancer tissue samples analyzed for whole genome, whole exome and RNA from more than 7,000 unique patients with mult... 
Printer Friendly Version
09/21/16NantHealth Partners with Children’s Hospital of Orange County to Revolutionize Pediatric Cancer Care Through the Use of GPS Cancer™
GPS Cancer will allow physicians to identify personalized treatments for children with rare, refractory or recurrent cancers for whom conventional approaches have proven unsuccessful Research partnership will provide new hope for an estimated 15,780 children between the ages of birth and 19 years of age who are diagnosed with cancer each year1 CULVER CITY, Calif.--(BUSINESS WIRE)--Sep. 21, 2016-- In an effort to accelerate and improve the course of pediatric cancer care, NantHealth, Inc... 
Printer Friendly Version
09/07/16Phoenix Children’s Hospital Selects NantHealth’s Molecular Testing Platform and Comprehensive Suite of Software Solutions for Precision Cancer Care
One of the nation's leading pediatric hospitals to adopt GPS Cancer™, a comprehensive molecular testing platform for personalized cancer therapy, for its patients and self-insured employee population NantHealth's decision support, patient engagement, care coordination, and analytics solutions to help Phoenix Children's advance population health and improve value-based outcomes CULVER CITY, Calif.--(BUSINESS WIRE)--Sep. 7, 2016-- ... 
Printer Friendly Version
08/09/16NantHealth Reports Strong 2016 Second-Quarter Revenues and Continued Progress on GPS Cancer and NantOS Platform
Total Quarterly Net Revenues Increased 167% to $31.5 Million from $11.8 Million Total Six-Month Net Revenues More than Doubled to $50.9 Million from $23.5 Million Raised Net Proceeds of Approximately $83.2 Million from Successful IPO in June 2016 GPS Progress: Increased to 200,000 Covered Cancer Lives with Three New Payer Agreements, Bringing Total to Six Payers Covering GPS ... 
Printer Friendly Version
08/03/16Sanford Health Selects NantHealth's eviti Platform to Deliver Efficient, Evidence-Based Oncology Decision Support for Treatment of Cancer Patients
Major U.S. health system brings award-winning comprehensive clinical decision support to the upper Midwest CULVER CITY, Calif.--(BUSINESS WIRE)--Aug. 3, 2016-- NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that Sanford Health, one of the largest health systems in the nation, has entered into a commercial license agreement for the use of its eviti®, the evidence... 
Printer Friendly Version
08/02/16NantHealth to Report 2016 Second-Quarter Financial Results and Host Conference Call on Tuesday, August 9
CULVER CITY, Calif.--(BUSINESS WIRE)--Aug. 2, 2016-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2016 second quarter on Tuesday, August 9, 2016 after market close. NantHealth management will host a conference call that same day at 2 p.m. PT (5 p.m. ET) to review the company’s performance and answer questions. The conferen... 
Printer Friendly Version
07/25/16NantHealth and University of Utah Establish Heritage 1K Project to Discover Genetic Causes of 25 Rare and Common Diseases
1,000 individuals will undergo whole genome sequencing and whole transcriptome sequencing using a novel genomic testing platform provided by NantHealth CULVER CITY, Calif.--(BUSINESS WIRE)--Jul. 25, 2016-- NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has partnered with the University of Utah in analyzing the entire genomic profiles of at least 1,000 ... 
Printer Friendly Version
06/17/16Cancer Breakthroughs 2020 and NantHealth Form Collaborative Melanoma and Sarcoma Working Group with Columbia University and UPMC to Accelerate Personalized Immunotherapy
Physicians And Researchers From Columbia University And UPMC To Collaborate On The Development Of Combination Immunotherapy Clinical Trial Protocols Informed By Comprehensive Genomic And Proteomic Profiling Augments Recently Announced Pediatric Cancer, Breast Cancer, Head And Neck Cancer And Radiation Working Groups CULVER CITY, Calif.--(BUSINESS WIRE)--Jun. 17, 2016-- NantHealth and Cancer Breakthroughs 2020, the nation's most comprehensive cancer collaborative initiativ... 
Printer Friendly Version
06/07/16NantHealth Announces Closing of Initial Public Offering
CULVER CITY, Calif.--(BUSINESS WIRE)--Jun. 7, 2016-- NantHealth, Inc. (formerly known as Nant Health, LLC), a next-generation, evidence-based, personalized healthcare company, announced today the closing of its initial public offering of 6,500,000 shares of its common stock at a price to the public of $14.00 per share (which reflects a 1-for-5.5 reverse stock split of NantHealth’s common stock effected in connection with the conversion of the company fro... 
Printer Friendly Version
06/07/16Cancer Breakthroughs 2020 Announces Breast Cancer Working Group with Multiple Leading Cancer Centers and the Launch of GPS Cancer at ASCO 2016
Physicians and researchers from leading institutions convened at the American Society of Clinical Oncology's (ASCO) 2016 Annual Meeting to collaborate on the development of combination immunotherapy clinical trial protocols for patients with breast cancer Key thought leaders to accelerate immunotherapy and precision medicine through GPS Cancer™ CULVER CITY, Calif.--(BUSINESS WIRE)--Jun. 7, 2016-- Cancer Breakthroughs 2020, the nation's most comprehensive cancer collaborative initia... 
Printer Friendly Version
06/03/16NantHealth Announces Commercial Availability of GPS Cancer™ and Launch of GPS Cancer Browser on a Secure Mobile Platform at the 2016 American Society of Clinical Oncology Annual Meeting
GPS CancerTM combines the power of quantitative proteomics with genomics and transcriptomics to understand the "molecular fingerprint" of a cancer patient's tumor enabling personalized treatment options First cancer test to better inform chemotherapy choice with quantitative measurement of known drug resistance and chemo sensitivity protein biomarkers present in patient's cancer cells Informed clinical decision support for taxanes, platinum and vinca alkaloids, the backbone of chem... 
Printer Friendly Version
06/01/16NantHealth Announces Pricing of Initial Public Offering
CULVER CITY, Calif.--(BUSINESS WIRE)--Jun. 1, 2016-- NantHealth, Inc. (formerly known as Nant Health, LLC), a next-generation, evidence-based, personalized healthcare company, announced today the pricing of its initial public offering of 6,500,000 shares of its common stock at a price to the public of $14.00 per share (which reflects a 1-for-5 1/2 reverse stock split of NantHealth’s common stock effected in connection with the conversion of the company f... 
Printer Friendly Version
05/16/16NantHealth Launches NaviNet Open Claims Management Application Suite
by Jen Hodson | May 16, 2016 | Powerful new suite of payer-sponsored claims applications that lower administrative costs, enhance operating efficiency and eliminate manual workflows for payers and their provider networks. CULVER CITY, Calif. – May 16, 2016 – NantHealth, LLC, a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses, today announced the launch of NaviNet Open Claims Mana... 
Printer Friendly Version
05/10/16NantHealth Announces New Expanded Coverage with Self-Insured Employers, Insurance Payers, and Health Systems for GPS Cancer, a Unique Comprehensive Molecular Test to Help Guide Treatment for Cancer Care
Bank of America, Phoenix Children's Hospital, Sanford Health become first national and regional self-insured employers to cover next-generation whole genome sequencing and proteomics for various cancersSanford Health Plan follows Independence Blue Cross's decision to make GPS Cancer testing available, accelerating the mission of Cancer Breakthroughs 2020, and expanding the ecosystem of institutions who offer and cover GPS Cancer test May 10, 2016 08:00 AM Eastern Daylight Tim... 
Printer Friendly Version
05/07/16Patrick Soon-Shiong, M.D., Honored as Guest Lecturer at American Urological Association 2016 Annual Meeting
by Jen Hodson | May 7, 2016 | Lecture highlights "Cancer Breakthroughs 2020" Urology to largest worldwide gathering of urologists San Diego, CA – May 7, 2016 – Patrick Soon-Shiong, M.D., founder and CEO of NantWorks, and leader of the Cancer Breakthroughs 2020 program, will deliver the Ramon Guiteras Lecture, titled "Cancer Breakthroughs 2020 Urology," at the American Urological Association Annual Meeting, May 6-10, 2016, at the San Diego Convention Center in San Diego, California. Now in its ... 
Printer Friendly Version
04/29/16Dr. Patrick Soon-Shiong Honored at the Vatican with the 2016 Pontifical Key Visionary Award
CULVER CITY, Calif. and VATICAN CITY – April 29, 2016 – Today, Dr. Patrick Soon-Shiong, who grew up in Apartheid South Africa and has dedicated his life to pioneering novel cellular therapies for diabetes and cancer, including the development of the revolutionary cancer drug Abraxane, was honored at the Vatican with the 2016 Pontifical Key Visionary Award. The award, presented by His Eminence Gianfranco Cardinal Ravasi, President of the Pontifical Council for Culture, recognizes m... 
Printer Friendly Version
04/20/16Dr. Patrick Soon-Shiong Honored with the 2016 Franklin Institute Bower Award
by Jen Hodson | Apr 20, 2016 | NantWorks CEO and Cancer Breakthroughs 2020 founder recognized for visionary leadership and commitment to improving health quality and transforming cancer careKeynote address on Cancer Breakthroughs 2020 and the Future of Medicine at the Franklin Institute on April 21   CULVER CITY, Calif. – April 20, 2016 – The Franklin Institute has awarded Dr. Patrick Soon-Shiong, NantWorks CEO and leader of the Cancer Breakthroughs 2020 program, with the prestigiou... 
Printer Friendly Version
03/03/16NantHealth Deploys First-Ever Time Saving Solution to Singapore Hospital Systems
by Jen Hodson | Mar 3, 2016 | VitalsConX represents NantHealth's newest solution to the company's technology platform bringing interoperability, connectivity and real-time decision support to clinicians at the point of care CULVER CITY, CA – March 3, 2016 – NantHealth, LLC, a transformational company combining the power of genomic science and healthcare IT through a highly scalable, cloud-based platform, today announced the deployment of its VitalsConX software solution in Singapore... 
Printer Friendly Version
02/24/16NantHealth to Showcase World-Class Portfolio of Healthcare IT and Genomics Solutions at HIMSS16 in Las Vegas
by Jen Hodson | Feb 24, 2016 | Recent technology acquisitions and Genomic Proteomic Sequencing (GPS) testing to help advance population health, value-based outcomes, and next-generation standard of cancer care NantHealth to exhibit in booth #5554 and at the HIMSS Interoperability Showcase February 24, 2016 08:00 AM Eastern Standard Time CULVER CITY, Calif.–NantHealth, LLC, a transformational company converging the power of genomic science and healthcare IT through a highly scalable clo... 
Printer Friendly Version
02/22/16Nant Leaders to Share Vision of Cancer Breakthroughs 2020 Program at Premier Oncology Event
by Jen Hodson | Feb 22, 2016 | Dr. Patrick Soon-Shiong keynotes on breakthroughs in immuno-oncology including development of Genomic Proteomic Sequencing test for cancer (GPS Cancer)Phoenix – February 22, 2016 – NantWorks, LLC, NantKwest (Nasdaq: NK), and NantHealth, LLC  today announced the scheduled discussion topics at the eighth annual Cancer Center Business Summit, a premier oncology event with this year's theme, "Oncology Care Transformation: What's Working and What Lies Ahead." The... 
Printer Friendly Version
01/11/16Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer
Large Pharma, Biotech, Major Payer, Fortune 50 Company, Academia and Community Oncologists Join Forces to Announce Launch of Cancer Breakthroughs 2020 ProgramNation's first insurance coverage of next generation whole genome sequencing and proteomic diagnostic platform in cancer patients‎Next generation sequencing ‎and precision medicine evolving from research to the clinical trial and cancer care settingCoalition to design, initiate and complete randomized clinical trials at all stages of cancer... 
Printer Friendly Version
01/11/16Nation’s First Insurance Coverage of Next-Generation Whole Genome Sequencing and Proteomic Diagnostic Platform Announced by Independence Blue Cross and NantHealth in the War Against Cancer
With Today's Announcement Next-Generation Sequencing ‎And Precision Medicine Has Evolved From Research To The Clinical Cancer Setting:CLIA-Certification of a Comprehensive Whole Genome tumor normal DNA, RNA and Quantitative Proteomic Sequencing Test (GPS Cancerä)Insurance coverage for GPS in patients with CancerAdoption of a payer-provider web-based collaboration platform, called NaviNet Open, enabling doctors and payers to share information in real time with access to over 90% of covered lives ... 
Printer Friendly Version
01/05/16NantWorks and NantHealth Complete Acquisition of NaviNet, America’s Leading Healthcare Collaboration Network
Acquisition scales NantHealth's cloud-based platform of services to deliver interoperability, connectivity, real-time decision support and a single sign-on operating system to over 450,000 active provider users and all-payer access to 450+ commercial and government plans nationally, covering almost 100 million lives and over 30 million monthly transactionsNaviNet Open will serve as a nationwide scalable, real-time access point and secure web-based portal for patients and providers to receive bre... 
Printer Friendly Version